Substance / Medication

Etravirine

Overview

Active Ingredient
etravirine
RxNorm CUI
475969

Indications

Microbiology (12.4) [see Clinical Studies (14)] Etravirine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients and pediatric patients 2 years of age and olderand.

Labeler: AvKAREUpdated: 2026-01-13T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers.
Hammond Kyle P, Wolfe Pamela, Burton James R et al. · J Acquir Immune Defic Syndr · 2013
PMID: 23075915RCT
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
Fätkenheuer G, Duvivier C, Rieger A et al. · J Antimicrob Chemother · 2012
PMID: 22210755RCT
Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.
Song Ivy, Borland Julie, Min Sherene et al. · Antimicrob Agents Chemother · 2011
PMID: 21555764RCTFull text (PMC)
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
Clotet Bonaventura, Clumeck Nathan, Katlama Christine et al. · J Antimicrob Chemother · 2010
PMID: 20801782RCT
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.
Boffito Marta, Jackson Akil, Lamorde Mohammed et al. · J Acquir Immune Defic Syndr · 2009
PMID: 19620877RCT
A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.
Schöller-Gyüre Monika, Kakuda Thomas N, De Smedt Goedele et al. · Br J Clin Pharmacol · 2008
PMID: 18492125RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Etravirine (substance)
SNOMED CT
432121008
UMLS CUI
C1456409
RxNorm CUI
475969
Labeler
AvKARE

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.